ライフサイエンスコーパス: screening system

1 ity to ototoxin in a high-content phenotypic screening system.

2 hlamydial serovars was used for testing this screening system.

3 a cell-based global protein stability (GPS) screening system.

4 ytidine (5Aza-dC)-induced senescence bypass) screening system.

5 olated using a newly established yeast-based screening system.

6 protein using a bacterial two-hybrid library screening system.

7 m, and L. monocytogenes in food samples as a screening system.

8 e of an effective high-throughput phenotypic screening system.

9 have employed an Alu-PCR-based hybridization screening system.

10 n and deployment of more equitable LLM-based screening systems.

11 xisting microfluidic devices and large-scale screening systems.

12 and the lack of rapid, sensitive biological screening systems.

13 high-throughput genomics and innovative drug-screening systems.

14 very of therapeutic compounds through simple screening systems.

15 are most commonly applied in high-throughput screening systems.

16 uch as clinical analysis and high-throughput screening systems.

17 R in establishing a conformation-guided drug screening system, advancing the cell- and structure-base

18 Through phenotypic screening, systems analysis, and rigorous experimental v

19 A expression library in the yeast one-hybrid screening system and obtained the cDNA clone NT2.

20 red nanoparticles (ENP) in a high-throughput screening system and places this model in an adverse out

21 It is an ideal technique for high-throughput screening systems and demonstrates the power of lab-on-a

22 could be valuable for improving gene banks' screening systems and for crop breeding.

23 High-throughput cell-culture screening systems are also being developed.

24 less developed countries where no effective screening systems are available.

25 implementation of a barcoded high-throughput screening system as a means to identify the lung-targeti

26 Here, using a systemic screening system based on a luciferase reporter gene ass

27 We built a fully automated cell culture screening system based on a microfluidic chip that creat

28 Using a mammalian screening system based on transcriptional activation by

29 of 15 in silico designed siRNAs, an in vitro screening system based on vectors expressing SARS-CoV-2

30 e report the development of an antifiloviral screening system, based on a pseudotyping strategy, and

31 Testing of the PCR screening system confirmed it to be highly specific and

32 Thus, our novel screening system could be a useful tool to identify and

33 We present an ultra-sensitive screening system coupled to an ex vivo prion organotypic

34 Here, we used an in vivo CRISPR activation screening system coupled with positive selection to iden

35 Such a screening system detects even low levels of protein spli

36 This screening system does not require deep sequencing and ma

37 systems, thereby providing a high-throughput screening system enabling evaluation of MBI-associated h

38 interspaced short palindromic repeats)-based screening system for combinatorial genetic manipulation

39 A high-throughput screening system for homogeneous catalyst discovery has

40 We have set up a yeast growth-based screening system for mutant D-xylose transporters that a

41 e interaction with the enzyme and a powerful screening system for new inhibitors.

42 ssay should be valuable as a high-throughput screening system for protein splicing inhibitors as pote

43 munosorbent assay (ELISA) was developed as a screening system for rapid detection of clenbuterol, whi

44 lished a robust and specific high-throughput screening system for synthetic defense elicitors that ca

45 Thus, we have developed a microarray-based screening system for testing the effects of small molecu

46 ide RNAs targeting both ends of an NCRE as a screening system for the Cas9-mediated deletion of thous

47 To establish a screening system for the humoral response to autoimmunog

48 In this paper, we describe an in vivo screening system for the isolation of mutations or inhib

49 New screening systems for enantioselectivity and protein sol

50 ll as for novel versatile agonist/antagonist screening systems for identification of novel therapeuti

51 With respect to the needs of productive screening systems for robust and reproducible measuremen

52 The automated screening system had a sensitivity of 97.6% (95% confide

53 These validation data suggest that the screening system has good performance in adipogenic pred

54 ntation of an automated diabetic retinopathy screening system in a primary care clinic serving a low-

55 he performance of the Cellenium 160 US urine screening system in comparison to that of the semiquanti

56 ere, to address it, we develop a directional screening system in human cells to evolve the deaminase

57 lustrate the ability of direct combinatorial screening systems in cancer patients for identification

58 the full capabilities of our high-throughput screening system, including generation of spectroscopic

59 ificity, we developed an unbiased cell-based screening system involving multiple rounds of infection

60 Thus, developing an appropriate in vitro screening system is critical to prioritize which of the

61 the conventional high-throughput cell-based screening system, its limitation is obvious, together wi

62 Miniaturization of such screening systems may overcome problems associated with

63 lying a computational workflow for parameter screening, systems modeling identified that apoptosis ex

64 Our proof-of-concept experiments verify the screening system of farm-derived dust samples as suitabl

65 The model provides a rapid method for screening system parameters for the potential to mediate

66 tenance using the Lazy Piggy in vivo genetic screening system, providing a therapeutic target.

67 ved human p53 mutants, (b) demonstrating the screening system's efficiency through identification of

68 By using a high-throughput screening system targeting host protein kinases, we iden

69 ch has been impaired by the lack of a robust screening system that can be used to investigate interac

70 a malignant melanoma model, we established a screening system that employs the NanoString nCounter pl

71 ed an in vivo Drosophila X virus (DXV)-based screening system that identifies altered sensitivity to

72 Our findings describe a new screening system that identifies molecules and pathways

73 ency is poor and there is a lack of in vitro screening systems that predict transfection efficacy.

74 Establishing state-of-the-art screening systems that rely on fluorescent or luminescen

75 tifying patients most likely to benefit from screening, systems that facilitate their application, an

76 xpanded a CRISPR inhibition and Cas9-editing screening system to discover factors indirectly modulati

77 e a "two cell type" whole genome CRISPR-Cas9 screening system to discover key regulators of tumor sen

78 aromyces cerevisiae was also used as a rapid screening system to evaluate tomato antioxidant capacity

79 t study we employed a yeast-based two-hybrid screening system to identify BAT3 (HLA-B-associated tran

80 cells and established a flow cytometry-based screening system to identify compounds that increase MBN

81 We describe a synthetic, high-throughput screening system to identify compounds that inhibit acti

82 genesis and a retrovirus-mediated expression screening system to identify constitutively active forms

83 ll death we have designed a loss-of-function screening system to identify genes that are essential fo

84 We have developed and used a Drosophila screening system to identify genes that are functionally

85 ition of Saccharomyces cerevisiae as a model screening system to identify human genes that regulate c

86 n inexpensive nonradioactive high-throughput screening system to identify new ACC inhibitors.

87 le-nt) resolution and describe a directional screening system to identify novel SaCas9 variants with

88 We have used a FACS-based genome-wide screening system to identify transcriptional alterations

89 s into apoE biology and establishes a robust screening system to monitor apoE conformation.

90 Hence, development of a high-throughput screening system to monitor temporal changes of IP(3) is

91 A multiplexed screening system to quickly determine the binding affini

92 potential of a semiautonomous breast cancer screening system to reduce false positives, unnecessary

93 s), artificial-intelligence-based diagnostic screening system to streamline the molecular diagnosis o

94 on by KSHV, we used two different gene array screening systems to examine the expression profile of e

95 C. elegans has been used in mutation-based screening systems to identify novel virulence-related mi

96 Screening systems to identify receptors for RvD1 gave tw

97 tems, underscoring the importance of in vivo screening systems to uncover physiologically relevant re

98 V-MP) were used, in a modified phage-display screening system, to identify peptides capable of intera

99 c CD8, CD4, and regulatory T cell neoepitope screening system, to perform an advanced neoantigen anal

100 Most applications in droplet microfluidic screening systems use fluorogenic substrates to measure

101 represents an open-source contractile force screening system useful for drug screening and tissue en

102 dge, we developed the first morphology-based screening system using adult cortical neurons and the fi

103 on was examined by a cell-based high content screening system using LysoTracker, which was followed b

104 We have developed an activity-based aptamer screening system using magnetic beads templated with apt

105 vior-based, automated, and quantitative drug screening system using this dnc-1 KD model together with

106 le and fixed-location ultra-widefield camera screening system was able to be deployed to carry out th

107 the usefulness of this cell model as a drug screening system was assessed by determining the express

108 The feasibility of the screening system was confirmed by constructing a protein

109 A high throughput screening system was developed to measure H(2)O(2)-suppo

110 The applicability of the screening system was evaluated by analysis of various ty

111 tional, TWO-ROP 36-week, and TWO-ROP 40-week screening systems was 1.95, 1.43, and 0.99, respectively

112 el bacterial display/flow cytometric library screening system we isolated Fc variants that bind to Fc

113 Using the screening system, we have established conditions under w

114 Using a yeast two-hybrid screening system, we have identified Ral-binding protein

115 Using the yeast two-hybrid screening system, we have isolated and characterized the

116 man liver cDNA library in a yeast two-hybrid screening system, we have isolated several positive clon

117 Using a newly developed high-throughput screening system, we identified inhibitors and activator

118 Using an in vivo CRISPR screening system, we identified SPP2 as a secreted facto

119 Using a cell-based miRNA target screening system, we identify hypoxia-inducible factor-2

120 Using a yeast genetic screening system, we identify Lhx3 point mutants that bi

121 In the in vitro screening systems, we demonstrated that 1) anti-CD105 (E

122 volume; compared to state-of-the-art robotic screening systems, we perform the entire assay with a 1,

123 cell targets, we developed a hybrid genetic screening system where the Sleeping Beauty (SB) transpos

124 We anticipate that the CcdB-based in vivo screening system will find uses in the analysis of struc

125 PDAC were identified by using a CRISPR-Cas9 screening system with a custom sgRNA library.

126 a novel surface display Y2H (sdY2H) library screening system with uniquely integrated surface displa

127 Such a screening system yielded a plasmid with a 4.8-kb insert.